Tocilizumab, an IL-6 inhibitor used in autoimmune diseases like rheumatoid arthritis and giant cell arteritis, was not administered to our patient cohort, thus precluding its evaluation in those with elevated IL-6 levels. Here, IL6 is linked to autoimmune disease.